L. Eissing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
L. Eissing has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
A. Enk
Department of Dermatology, Heidelberg University Hospital, Heidelberg, Germany
2 shared publicationsI. Schäfer
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
2 shared publicationsK. Strömer
Dermatology Practice Mönchengladbach, Mönchengladbach, Germany
2 shared publicationsM. Augustin
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
2 shared publicationsM. Reusch
Tibarg Dermatology Group Practice, Hamburg, Germany
2 shared publicationsM.A. Radtke
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
2 shared publications
Latest Publications
- 14 July 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (12) , 2124-2130
Perception and image of dermatology in the German general population 2002–2014
Background In contrast to other European countries, dermatologists in Germany provide health care for a broad spectrum of diseases of the skin and mucous membranes. Current population‐based data on the perception of dermatology were lacking to date. Objective Analysis of the perception of dermatology from the general population's perspective with regard to utilization, satisfaction and responsibility. Methods Nation‐wide survey on awareness, utilization, rating and image of dermatology in October 2014 through computer‐assisted telephone interviews on a representative sample of the adult general population (n = 1015), performed by the FORSA institute. Results Dermatologists as a medical specialist group are familiar to 88% of the population (2002: 65%), and approx. 82% of respondents underwent dermatological treatment in the past. Satisfaction with this treatment is high to very high in 80–90% of respondents. The majority (60–80%) name dermatologists as the desired primary provider of care for the largest share of common skin diseases. For allergic diseases, mucous membrane diseases, venous disorders and paediatric skin diseases, this rate is significantly below 50%. Conclusions In Germany, dermatologists are perceived and valued as providers of care. In the case of skin cancer and chronic inflammatory skin diseases, they are experienced as primary care givers, whereas they are associated less frequently than their competence would justify with providing treatment for allergic and mucous membrane diseases and venous disorders. Further education of the general public and medical profession is required.
- 14 July 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (12) , 2124-2130
Perception and image of dermatology in the German general population 2002–2014
Background In contrast to other European countries, dermatologists in Germany provide health care for a broad spectrum of diseases of the skin and mucous membranes. Current population‐based data on the perception of dermatology were lacking to date. Objective Analysis of the perception of dermatology from the general population's perspective with regard to utilization, satisfaction and responsibility. Methods Nation‐wide survey on awareness, utilization, rating and image of dermatology in October 2014 through computer‐assisted telephone interviews on a representative sample of the adult general population (n = 1015), performed by the FORSA institute. Results Dermatologists as a medical specialist group are familiar to 88% of the population (2002: 65%), and approx. 82% of respondents underwent dermatological treatment in the past. Satisfaction with this treatment is high to very high in 80–90% of respondents. The majority (60–80%) name dermatologists as the desired primary provider of care for the largest share of common skin diseases. For allergic diseases, mucous membrane diseases, venous disorders and paediatric skin diseases, this rate is significantly below 50%. Conclusions In Germany, dermatologists are perceived and valued as providers of care. In the case of skin cancer and chronic inflammatory skin diseases, they are experienced as primary care givers, whereas they are associated less frequently than their competence would justify with providing treatment for allergic and mucous membrane diseases and venous disorders. Further education of the general public and medical profession is required.
- 28 February 2017
- Published by Springer Nature in Die Dermatologie
- Vol. 68 (5) , 371-376
Die Wahrnehmung des gesetzlichen Hautkrebsscreenings in der Allgemeinbevölkerung
- 28 February 2017
- Published by Springer Nature in Die Dermatologie
- Vol. 68 (5) , 371-376
Die Wahrnehmung des gesetzlichen Hautkrebsscreenings in der Allgemeinbevölkerung
- 2 May 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (7) , 1100-1106
Psoriasis registries worldwide: systematic overview on registry publications
Background: Safety and efficacy of new treatments are analyzed in clinical trials but their capacity to show potential effects of long‐term treatment and more than short latency of onset is limited. To meet this challenge, patient registries (of treatments or diseases) collect prospective data of real‐world patients in daily practice without tight selection of patients.Objective: The aim of this article was to identify existing psoriasis patient registries by published articles and evaluation of monitored treatment classes, patients, research questions addressed, and measurement instruments implemented.Materials & Methods: A systematic review of Medline (PubMed) and Embase (Ovid) databases for publications on psoriasis patient registries, including cross‐validation was conducted October 2015.Results: 14 patient registries for long‐term observation of psoriasis patients in real‐world care were identified. Registries were established since 2005, the majority is located in Europe. The number of published studies from single registries ranged from 1 to 10. Most registries include patients treated by conventional systemics as well as biologics. The number of patients analyzed ranged from 35 to >12 000 patients. The publications mostly addressed safety issues or treatment outcomes, followed by baseline description, drug survival, predictor analyses, and treatment patterns.Conclusion: A variety of local, national, and international patient registries collect longitudinal data on (systemic) psoriasis treatment. The number of publications reflect the main registry objectives of safety and effectiveness, with additional therapy‐related investigations being addressed as well. Based on the information from publications, the combination of data from these registries will involve many methodological challenges. To gain comparability and combinability of cohorts and data across registries, further harmonization of data collection is demanded.
- 2 May 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (7) , 1100-1106
Psoriasis registries worldwide: systematic overview on registry publications
Background: Safety and efficacy of new treatments are analyzed in clinical trials but their capacity to show potential effects of long‐term treatment and more than short latency of onset is limited. To meet this challenge, patient registries (of treatments or diseases) collect prospective data of real‐world patients in daily practice without tight selection of patients.Objective: The aim of this article was to identify existing psoriasis patient registries by published articles and evaluation of monitored treatment classes, patients, research questions addressed, and measurement instruments implemented.Materials & Methods: A systematic review of Medline (PubMed) and Embase (Ovid) databases for publications on psoriasis patient registries, including cross‐validation was conducted October 2015.Results: 14 patient registries for long‐term observation of psoriasis patients in real‐world care were identified. Registries were established since 2005, the majority is located in Europe. The number of published studies from single registries ranged from 1 to 10. Most registries include patients treated by conventional systemics as well as biologics. The number of patients analyzed ranged from 35 to >12 000 patients. The publications mostly addressed safety issues or treatment outcomes, followed by baseline description, drug survival, predictor analyses, and treatment patterns.Conclusion: A variety of local, national, and international patient registries collect longitudinal data on (systemic) psoriasis treatment. The number of publications reflect the main registry objectives of safety and effectiveness, with additional therapy‐related investigations being addressed as well. Based on the information from publications, the combination of data from these registries will involve many methodological challenges. To gain comparability and combinability of cohorts and data across registries, further harmonization of data collection is demanded.
- 4 November 2015
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (4) , 569-575
Barriers to guideline‐compliant psoriasis care: analyses and concepts
Despite the availability of effective therapeutics and evidence‐based treatment guidelines, a substantial proportion of patients with moderate‐to‐severe psoriasis does not receive appropriate care. This under‐provision of health care may cause further worsening of health, remarkable limitations of the patient's quality of life, and indirect costs for the health care system. In order to provide guideline‐compliant care for every psoriasis patient, it is important to identify barriers obstructing optimal care. Studies have identified various barriers on the physician's and on the patient's side; however, respective studies approached only single barriers, and not all of them in the context of psoriasis. Other publications that describe barriers systematically did not focus on psoriasis either. The objective of this literature review was to identify barriers and facilitators, based on studies analysing quality of care and single barriers, resulting in a comprehensive model of causal factors. Our analyses revealed three categories of barriers – patient‐related, physician‐related and external factors: On the patient side, we found non‐adherence to therapies to be an important barrier, often in close association with psychiatric factors. Barriers on the physician's side predominantly are incomplete knowledge of the guidelines as well as the complexity of psoriasis comorbidity. In some countries, payment for patients with complex disease status is poor and inconsistent reimbursement regulations potentially interfere with optimal care. The current analysis indicates that most barriers are interdependent. Thus, measures approaching related barriers simultaneously are required. To improve care for psoriasis patients, further studies systematically addressing all potentially relevant barriers in conjoint are needed.
- 4 November 2015
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (4) , 569-575
Barriers to guideline‐compliant psoriasis care: analyses and concepts
Despite the availability of effective therapeutics and evidence‐based treatment guidelines, a substantial proportion of patients with moderate‐to‐severe psoriasis does not receive appropriate care. This under‐provision of health care may cause further worsening of health, remarkable limitations of the patient's quality of life, and indirect costs for the health care system. In order to provide guideline‐compliant care for every psoriasis patient, it is important to identify barriers obstructing optimal care. Studies have identified various barriers on the physician's and on the patient's side; however, respective studies approached only single barriers, and not all of them in the context of psoriasis. Other publications that describe barriers systematically did not focus on psoriasis either. The objective of this literature review was to identify barriers and facilitators, based on studies analysing quality of care and single barriers, resulting in a comprehensive model of causal factors. Our analyses revealed three categories of barriers – patient‐related, physician‐related and external factors: On the patient side, we found non‐adherence to therapies to be an important barrier, often in close association with psychiatric factors. Barriers on the physician's side predominantly are incomplete knowledge of the guidelines as well as the complexity of psoriasis comorbidity. In some countries, payment for patients with complex disease status is poor and inconsistent reimbursement regulations potentially interfere with optimal care. The current analysis indicates that most barriers are interdependent. Thus, measures approaching related barriers simultaneously are required. To improve care for psoriasis patients, further studies systematically addressing all potentially relevant barriers in conjoint are needed.